 
 Clinical Trial Protocol : THR-1442 -C-418 
Study Title:  Efficacy and safety of EGT0001442 compared with placebo in patients 
with type 2 diabetes mellitus inadequately controlled by [CONTACT_614752] -diabetes agent.  
Study Number:  THR -1442 -C-418 
Study Phase:  [ADDRESS_815311] Name:  [CONTACT_614792]0001442 tablet  
IND Number:  103822  
Indication:  Type 2 diabetes mellitus  
Investigators:  Multiple center  
Sponsor:  Theracos, Inc.  
Sponsor Contact:  [CONTACT_614753] t Collinson, Ph.D.  
Theracos, inc.  
[ADDRESS_815312]  
Sunnyvale, CA [ZIP_CODE]  
Phone: [ADDRESS_815313]  
[LOCATION_011], MA [ZIP_CODE]  
Telephone number:  [PHONE_12708]  
Fax number:  617 -726-2879  
E-mail: [EMAIL_11688]  
 
 Date  
Original Protocol:  02 February 2011  
 
Confidentiality Statement  
The following confidential information is the property of Theracos, Inc.  As long as the 
information contained in this protocol has not been published, it may only be used when 
permission has been obtained from Theracos  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -1442 -C-418  02 February 2011   
   
 
Confidential  Page 2 of 61 
 SYNOPSIS  
Sponsor:  
Theracos, Inc.  
Name [CONTACT_2756]:  
EGT0001442 tablet  
Name [CONTACT_3261]:  
EGT0001442  
Study Title :  
Efficacy and safety of EGT0001442 compared with placebo in patients with type 2 diabetes 
mellitus inadequately controlled by [CONTACT_614754] -diabetes agent.   
Study Number:  
THR -1442 -C-418 
Study Phase:  3 
Primary Objective(s):   
To assess the efficacy of EGT0001442 in lowering HbA1c at week 24 compared with 
placebo  
Secondary Objective(s):  
 To assess the efficacy of EGT0001442 in lowering FPG at weeks 2 and 24  compared 
with placebo  
 To assess the efficacy of EGT0001442 based on the proportion of subjects in the 
EGT0001442 group reaches the American Diabetes Association (ADA) target HbA1c 
of <7% compared with placebo  
 To assess the effect of EGT0001442 on systolic and diastolic blood pressure 
compared with placebo  
 To assess the effect of EGT0001442 on body weight compared with placebo  
 To assess the change in HbA1c change over time, week 1 to week 96  
 To assess the safety of EGT0001442  in patients with T2DM  
 
Study Design:  
A multinational, 2 arm parallel groups , randomized, double -blind  placebo -controlled study to 
compare the treatment of once daily EGT0001442 at 30 mg with matching placebo in 
treatme nt-naïve type 2 diabetic patients (i.e. not taking an antihyperglycaemic agent for ≥16 
weeks prior to study entry) or with diet and exercise in combination with one oral 
antidiabetes drug  and an HbA1c of 7-10%.  Approximately 300 eligible subjects will start a 
2-week placebo run -in period prior to  being randomly assigned to either once daily 
EGT0001442 or placebo  in a 1:[ADDRESS_815314] completed the  
main treatment period  will continue to receive study drug  until week 96 .  In the treatment 
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -[ADDRESS_815315] additional antidiabetic  
therapy added to the study drug  consistent with treatment recommendations for type 2 
diabetes .   
 
Study Population  and main eligibility criteria :  
Approximately 300 patients that are inadequately controlled by [CONTACT_614755] a single oral anti -diabetes agent, randomized 1:1 to placebo and EGT0001442  
 Type 2 diabetes per the America n Diabetes Association criteria  
 Male or female  
 Age ≥ 18 years  
 Receiving one or no oral anti -diabetic agent and diet and exercise instruction  
 HbA1c between 7 and 10% at screening  
 Body mass index (BMI) ≤ 37 kg/m2 
 Fasting plasma glucose <2 50 mg/dL at screening for subjects not treated with oral 
anti-diabetic therapi[INVESTIGATOR_014]  
 Fasting plasma glucose <240 mg/dL at screening for subjects treated with anti -
diabetic therapie s 
 Fasting plasma glucose <2 50 mg/dL for all subjects at randomization  
Test Product, Dose, and Mode of Administration:   
EGT0001442 tablets 30  mg once daily by [CONTACT_614756]; Dose; and Mode of Administration:  
 Placebo – once daily by [CONTACT_614757]:  
 98 week (2wk run -in, 24 week primary evaluation, 72  week extension)  
Statistical Methods:   
The primary objective of this trial is to assess the efficacy of EGT0001442 in treatment -naïve 
type-2 diabetic patients or patients on a single oral anti -diabetic drug in combination with 
diet and exercise with an HbA1c between 7 and 10%.   Efficacy is defined as a significant 
reduction in HbA1c at week [ADDRESS_815316] of EGT0001442 on 
fasting glucose, blood pressure, body weight and the general safety of EGT0001442 in 
patients with T2DM will also be explored.  
Statistical analyses and summaries of safety and tolerability will be performed using SAS® 
software (SAS Institute, Cary, NC).  In all cases, significance will be judged at the =0.05 
level.  No multiplicity adjustment will be required for the single primary en dpoint.  
 
Date of Original Approved Protocol:  02 February 2011  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -[ADDRESS_815317] OF ABBREVIATION S AND DEFINITIONS OF  TERMS  ................................ ............ 8 
NO OBSE RVABLE ADVERSE EFFEC T LEVEL  ................................ ................................ ..9 
1 INTRODUCTION  ................................ ................................ ................................ ........... 11 
1.1 EGT0001442 for the treatment of type 2 diabetes mellitus  ................................ ...11 
1.1.1  Summary of non -clinical data with EGT0001442  ................................ .......12 
1.1.2  Summary of Clinical data with EGT0001442  ................................ ............. 12 
2 STUDY OBJECTIVES  ................................ ................................ ................................ ....14 
2.1 Primary O bjective(s)  ................................ ................................ .............................. 14 
2.2 Secondary Objective(s)  ................................ ................................ .......................... [ADDRESS_815318] an ................................ ................................ .............. 15 
3.2 Rationale for Study Design and Control Group  ................................ ..................... 17 
3.3 Study Duration and Dates  ................................ ................................ ...................... 18 
4 STUDY POPULATION SEL ECTION  ................................ ................................ ........... 19 
4.1 Study Population  ................................ ................................ ................................ ....19 
4.2 Inclusion Criteria  ................................ ................................ ................................ ...19 
4.3 Exclusion criteria  ................................ ................................ ................................ ...19 
5 STUDY TREATMENT(S)  ................................ ................................ .............................. 21 
5.1 Description of Treatment(s)  ................................ ................................ ................... 21 
5.1.1  Study Drug  ................................ ................................ ................................ ...21 
5.1.2  Placebo  ................................ ................................ ................................ ......... 21 
5.1.3  Rescue medications  ................................ ................................ ...................... 21 
5.2 Treatments Administered  ................................ ................................ ....................... 22 
5.3 Selection and Timing of Dose for Each Patient  ................................ ..................... 22 
5.4 Method of Assigning Patients to Treatment Groups  ................................ .............. 22 
5.5 Blinding ................................ ................................ ................................ .................. 22 
5.6 Concomitant Therapy ................................ ................................ ............................. 23 
5.7 Restrictions  ................................ ................................ ................................ ............ 24 
5.7.1  Prior Therapy  ................................ ................................ ............................... 24 
5.7.2  Fluid and Food Intake  ................................ ................................ .................. 24 
5.7.3  Patient Activity Re strictions  ................................ ................................ ........ 24 
5.8 Treatment Compliance  ................................ ................................ ........................... 24 
5.9 Packaging and Labeling  ................................ ................................ ......................... 25 
5.9.1  Study drug for main treatment period  ................................ .......................... 25 
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -[ADDRESS_815319] Retention at S tudy Site  ................................ .................... 25 
6 STUDY PROCEDURES  ................................ ................................ ................................ .26 
6.1 Informed Consent ................................ ................................ ................................ ...26 
6.2 Medical History  ................................ ................................ ................................ .....26 
6.3 Physical Examination ................................ ................................ ............................. 27 
6.4 Vital Signs  ................................ ................................ ................................ .............. 27 
6.5 Electrocardiography  ................................ ................................ ............................... 27 
6.6 Diet and exercise counseling  ................................ ................................ ................. 27 
6.7 Clinical Laboratory Tests  ................................ ................................ ....................... 27 
6.7.1  Laboratory Parameters  ................................ ................................ ................. 27 
6.7.2  Sample Collection, Storage, and Shippi[INVESTIGATOR_007]  ................................ .................. 28 
6.7.2. 1 HEMATOLOGY AND BLOOD  CHEMISTRY  ............................... 28 
[IP_ADDRESS]  URINALYSIS  ................................ ................................ .................... 29 
6.8 Dispensing Study Drug  ................................ ................................ .......................... 29 
6.9 Adverse Events Assessments  ................................ ................................ ................. 29 
6.9.1  Definitions ................................ ................................ ................................ ....29 
6.9.2  Eliciting and Reporting Adverse Events  ................................ ...................... 31 
6.9.3  Immediately Reportable Adverse Events (IRAE)  ................................ ........ 31 
6.9.4  Pregnancy  ................................ ................................ ................................ .....31 
6.9.5  Procedure for Breaking the Blind  ................................ ................................ 33 
6.9.6  Follow -up of Adverse Events  ................................ ................................ ......33 
[IP_ADDRESS]  FOLLOW -UP OF NON -SERIOUS ADVERSE EVEN TS ............... 33 
[IP_ADDRESS]  FOLLOW -UP OF POST STUDY SER IOUS ADVERSE 
EVENTS  ................................ ................................ ............................ [ADDRESS_815320]  ................................ ................................ .34 
[IP_ADDRESS]  GENIT OURINARY INFECTIONS  ................................ .................. 34 
[IP_ADDRESS]  RENAL AND URINARY DI SORDERS  ................................ .......... 34 
[IP_ADDRESS]  MAJOR ADVERSE CARDIO VASCULAR EVENT (MACE ) .......34 
[IP_ADDRESS]  HYPOGLYCEMIA ................................ ................................ ............ 34 
6.10  Concomitant Medication Asses sments  ................................ ................................ ..34 
6.11  Removal of Patients from the Trial or Study Drug  ................................ ................ 35 
6.12  Other Study Procedures  ................................ ................................ ......................... 35 
7 STUDY ACTIVITIES  ................................ ................................ ................................ .....36 
7.1.1  Visit 1 - Screening (weeks –5 to -2) ................................ ............................ 36 
7.1.2  Visit 2 – run-in period (day -14±3)  ................................ .............................. 36 
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -1442 -C-418  02 February 2011   
   
 
Confidential  Page 6 of 61 
 7.2 Primary Efficacy Phase  ................................ ................................ .......................... 37 
7.2.1  Visit 3 – procedures (Day 1 in Week 0)  ................................ ...................... 37 
7.2.2  Visit 4 – Procedures (week 2)  ................................ ................................ ......37 
7.2.3  Visit 5 – Procedures (week 6)  ................................ ................................ ......38 
7.2.4  Visit 6 – Procedures (week 12)  ................................ ................................ ....38 
7.2.5  Visit 7 – Procedures (week 18)  ................................ ................................ ....39 
7.2.6  Visit 8 – Procedures (week 24)  ................................ ................................ ....39 
7.3 Extension Phase  ................................ ................................ ................................ .....40 
7.3.1  Visit 9 – Procedures (week 36)  ................................ ................................ ....40 
7.3.2  Visit 10 – Procedures (week 48)  ................................ ................................ ..40 
7.3.3  Visit 11 – Procedures (week 60)  ................................ ................................ ..41 
7.3.4  Visit 12 – Procedures (week 72)  ................................ ................................ ..41 
7.3.5  Visit 13 – Procedures (week 84)  ................................ ................................ ..42 
7.3.6  Visit 14 – Procedures (week 96)  ................................ ................................ ..42 
7.3.7  Visit 15 – Exit Visit (week 97)  ................................ ................................ ....43 
7.4 Early Termi nation Procedures  ................................ ................................ ............... 43 
8 QUALITY CONTROL AND ASSURANCE  ................................ ................................ .45 
9 PLANNED STATISTICAL METHODS  ................................ ................................ ........ 46 
9.1 General Considerations  ................................ ................................ .......................... 46 
9.1.1  Handling Dropouts, Mu ltiples, Missing Data, and Outliers  ........................ 46 
9.1.2  Multiple Comparisons / Multiplicity  ................................ ........................... [ADDRESS_815321]  ................................ ................................ .49 
[IP_ADDRESS]  GENITOURINARY INFECT IONS  ................................ .................. 49 
[IP_ADDRESS]  MAJOR ADVERSE CARDIO VASCULAR EVENT (MACE ) .......49 
[IP_ADDRESS]  HYPOGLYCEMIA ................................ ................................ ............ 50 
[IP_ADDRESS]  RENAL AND URINARY DI SORDERS  ................................ .......... 50 
9.6.3  Clinical and Laboratory Events and Analyses  ................................ ............. 50 
9.6.4 Concomitant Medications  ................................ ................................ ............ 50 
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -[ADDRESS_815322] (IRB) or Independent Ethics Committee (IEC) 
Approval  ................................ ................................ ................................ ................ [ADDRESS_815323] of the Study  ................................ ................................ ................. 51 
10.4  Patient Information and Consent  ................................ ................................ ........... 52 
10.5  Patient Confidentiality  ................................ ................................ ........................... 52 
10.6  Study Monitoring  ................................ ................................ ................................ ...52 
10.7  Case Report Forms and Study Records  ................................ ................................ .53 
10.8  Protocol Violations/Deviations  ................................ ................................ .............. [ADDRESS_815324] OF APPENDICES  
Appendix 1  Schedule of Events  ................................ ................................ ..................... 57 
Appendix 2  Estimating glomerular filtration rate  ................................ .......................... 59 
Appe ndix 3  Sponsor Signatures ................................ ................................ ..................... 60 
Appendix 4  Investigator’s Signature  ................................ ................................ ............. 61 
 
 
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -[ADDRESS_815325]  
EC ethics committee  
ECG  electrocardiogram  
eGFR  estimating glomerular filtration rate 
FDA  Food and Drug Administration  
FPG fasting plasma glucose  
GCP  Good Clinical Practice  
GLP -1 glucagon -like peptide -1 
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -[ADDRESS_815326] level  
NYHA  [LOCATION_001] Heart Association  
OAM  oral anti -diabetic medications  
PD pharmacodynamics  
PK pharmacokinetics  
PP per protocol  
PT prothrombin  
RBC  red blood  cell (count)  
SAD  single ascending dose  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -[ADDRESS_815327] dose  
ULRR  Upper Limit of the Reference Range  
USP/NF  The [LOCATION_002] Pharmacopeia –National Formulary  
UTI urinary tract infections  
WBC  white blood cell (count)  
WHODRUG  World Health Organization Drug Dictionary  
WOCBP  Women of childbearing potential  
 
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -1442 -C-418  02 February 2011   
   
 
Confidential  Page 11 of 61 
 1 INTRODUCTION  
Diabetes mellitus, characterized by [CONTACT_157710] , is caused by [CONTACT_344256], 
resistance to insulin action, or a combination of both.  Approximately 285 million people 
worldwide, o r 6.6%, in the age group [ADDRESS_815328] diabetes in 2010.  The prevalence of 
diabetes is projected to be 438 million or 7.8% of the adult population by 2030  (Sicree et al., 
2010) . Over 90% of diabetic patients have type 2 diabetes  mellitus (T2DM) and over 80% of 
the type 2 diabetic patients are overweight or obese .  Several classes of agents for type 2 
diabetes are available for treating hyperglycemic conditions including insulin secretagogues, 
PPAR agonists, metformin, alpha glucosidase inhibitors, glucagon -like peptide 1 (GLP -1) 
analogues, and dipeptidyl peptidase 4 (DPP4) inhibitors.  Insulin and its analogues also are 
prescribed  for the treatment of type 2 diabetes  as the disease progresses.  However, a rapid 
rise in the number of adult type 2 diabetics has led to an increasing recognition that 
additional therapeutic modalities are needed to provide safe and effective reductions of 
elevated plasma glucose levels.  
The re nal Na+/glucose transpor ter SGLT2 (gene name [CONTACT_103095]5A2) is a member of a sugar 
transporter family that actively transports extracellular hexoses into cells using the driving 
energy of the transmembrane electrochemical potential for sodium ions.  Individuals w ith 
disruptions in the gene encoding SGLT2 exhibit prominent glucosuria in the absence of 
significant comorbidities (Santer et al., 2003; van den Heuvel et al., 2002) .  Significantly, 
neither hypoglycemia nor an increased incidence of urinary tract infections have  been 
reported in these individuals. The elimination of  glucose from the blood via urinary excretion 
has the potential to improve both fasting and postprandial hyperglycemia without increasing 
insulin secretion, causing weight gain, or inducing hypoglycemia.   
Phlorizin, a natural product inhibitor of SGLT1 an d 2, has been shown to produce urinary 
glucose excretion (UGE) and lower plasma glucose levels in several animal models 
(Ehrenkranz et al., 2005) .  Development of phlorizin was discontinued due to its rapid 
degradation by [CONTACT_614758] -phlorizin hydrolase and poor absorption from the gastrointestinal 
tract.  Several SGLT2 inhibitors are in dev elopment (Han et al., 2008; Neumiller et al., 
2010) .  Dapagliflozin is the SGLT2 inhibitor with the most extensive clinical dat a.  Early 
phase studies demonstrated sustained, dose -dependent glucosuria over 24 hours with once 
daily oral dosing (Komoroski et al., 2009a; Komoroski et al., 2009b) .  A double blind, 
placebo c ontrolled study showed that treatment with dapagliflozin for 6 months resulted in  
0.58% – 0.89% reduction of glycosylated hemoglobin A1c (HbA1c) from baseline compared 
with -0.23% in the placebo group with a placebo -subtracted changes in weight up to 1.1 kg 
(Ferrannini et al., 2010) .  Increased numbers of urinary tra ct and genital infections were 
observed in the treated groups.  
1.1 EGT0001442 for the treatment of type 2 diabetes mellitus  
EGT0001442, a candidate oral antidiabetic agent, is a potent, highly specific inhibitor  of the 
renal Na+/glucose transporter SGLT2.  It is a benzylbenzene C -glycoside of the same 
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -1442 -C-418  02 February 2011   
   
 
Confidential  Page 12 of 61 
 chemical structural class as dapagliflozin.  EGT00001442 elicits a prominent and predictable 
glucosuria in laboratory animals and in healthy and diabetic subjects in clinical studies.  
Several previous non -clinical and clinical studies were conducted with EGT0001474, a now -
discontinued crystalline formulation of EGT0001442 and L -proline in 1:2 stoichiometry.  
The mass ratio of EGT0001474 to EGT0001442 is 1.5:1. In this protocol, all studies 
performed with EGT0001474 are described in terms of the EGT0001442 content. For 
example if a study used 50 mg of EGT0001474 it is described as 33 mg of EGT0001442 
(delivered as proline cocrystal).  EGT0001474 and EGT0001442 have similar solubility in 
water, similar dissolution rate s when formulated as capsules, and show similar exposure in 
rat, monkey, and human studies.  
1.1.[ADDRESS_815329] level.  The NOAELs based on 
these studies are 6.7 and 20 mg/kg/day in rats and monkeys , respectively,  representing safety 
multiples of 8.1 and 19.6 relative to anticipated exposures in diabetic patient s at the planned 
clinical dose of 20 mg/day.  Chronic exposures produced similar toxicity profiles , with the 
additional  finding of  microvacuolization of renal cortical cells in monkeys after [ADDRESS_815330] 
fertility or in utero development up to the maximum tolera ted doses in rats and rabbits.  
Details of the toxicology findings are described in the Investigator’s Brochure.  
1.1.2  Summary of Clinical data with EGT0001442  
Clinical studies ha ve been conducted to evaluate safety, tolerability, pharmacokinetics (PK), 
pharmacodynamics (PD), metabolism, and efficacy of EGT0001442.  No death s or study  
drug related serious adverse event s (AEs) have been  reported in the clinical trials.   
EGT0001442 u p to 100 mg for up to 14 days was safe and tolerated  in healthy volunteers.  In 
a phase 2, double -blind, placebo -controlled study, subjects with type 2 diabetes mellitus were 
treated with EGT0001442 in doses of 5 to 50 mg or a placebo for 28 days.  The mos t 
frequently occurring AEs were headache (4% in the placebo and 11% in the treatment 
groups), pollakiuria (none in the placebo and 4% in the treatment groups), fatigue (7% in the 
placebo and 2% in the treated group), and nausea (4% in the placebo and 3% in  the treated  
group).  No hypoglycemia was reported.  Genital and urinary tract infections were observed 
in some subjects in the EGT0001442 treated groups, including  balanitis candida, urinary tract 
infection, bacterial vaginitis, v ulvovaginal candidiasis, and vulvovaginal mycotic infection . 
Urinary glucose excretion (UGE) was measured in healthy and diabetic subjects.  
EGT0001442 increased UGE in a dose -dependent and saturable manner.  The plateau in 
UGE corresponded to dosages of EGT0001442 above 20 mg/day .  EGT0001442 treatment in 
subject s with T2DM for 4 weeks was effective in reducing FPG by 24  to 41.6 mg/dL in the 
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -1442 -C-418  02 February 2011   
   
 
Confidential  Page 13 of 61 
 groups dosed with 5  to 50 mg/day EGT0001442.   Subjects receiving EGT0001442 also had a 
reduction in body weight, blood pressure, and postpran dial glucose compared to the changes 
in the placebo group.   Details of the safety and efficacy information are described in the 
Investigator’s Brochure  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -1442 -C-418  02 February 2011   
   
 
Confidential  Page 14 of 61 
 2 STUDY OBJECTIVES  
2.1 Primary Objective(s)  
The pri mary objective of this study is t o assess the efficacy of EGT0001442 in lowering 
HbA1c at week 24 compared with placebo . 
2.2 Secondary Objective(s)  
The secondary objective(s) of this study is (are):  
 To assess the efficacy of EGT0001442 in lowering FPG at weeks 2 and 24  compared 
with placebo  
 To assess the efficacy of  EGT0001442 based on the proportion of subjects in the 
EGT0001442 group reaches the American Diabetes Association (ADA) target HbA1c 
of <7%  compared with placebo  
 To assess the effect of EGT0001442 on systolic and diastolic blood pressure 
compared with placebo  
 To assess the effect of EGT0001442 on body weight compared with placebo  
 To assess the change in HbA1c change over time, week 1 to week 96  
 To assess the safety of EGT0001442  in patients with T2DM  
 
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -1442 -C-418  02 February 2011   
   
 
Confidential  Page 15 of 61 
 3 INVESTIGATIONAL PLAN  
3.1 Overall Study Design and Plan  
STUDY DESIGN  
THR -1442 -C-418 is a multinational, 2 arm parallel groups , randomized, double -blind  
placebo -controlled study to compare the treatment of once daily EGT0001442 at 30 mg with 
matching placebo in treatme nt-naïve type 2 diabetic patients (i.e. not taking an 
antihyperglycaemic agent for ≥16 weeks prior to study entry) or with diet and exercise in 
combination with one oral antidiabetes drug  and an HbA1c  of 7-10%.  Approximately 300 
eligible subjects will start a 2 -week placebo run -in period prior to  being randomly assigned to 
either once daily EGT0001442  or placebo , using a computer -generated allocation schedule, 
in a 1:[ADDRESS_815331] additional antidiabetic  therapy added to the study drug  
consistent with treatment re commendations for type 2 diabetes.   The primary analysis is to 
assess whether EGT0001442 is superior to placebo based on HbA1c change from baseline to 
week 24.    
RESEARCH METHODS AND PROCEDURES  
At screening visit, subjects who meet all the inclusion criter ia, none of the exclusion criteria, 
and who consent to participate in the study will receive counseling for appropriate diet and 
exercise.  Those who are on an oral antidiabetic medication (OAM) will discontinue the 
medication and receive placebo in this r un-in prior for 14 ± 3 days.   Eligible diabetic subjects 
who are treatment naïve and who control their hyperglycemia through diet and exercise will 
also receive placebo and the hyperglycemia will be monitored to ensure that their fasting 
blood glucose leve ls remain below 250 mg/dL during this interval of 14 ± 3 days.   
After the run -in period, approximately 300 subjects will complete the baseline assessment on 
day 1 after overnight fasting to confirm their eligibility.  The subjects that remain eligible 
will be randomly assigned to one of the 2 treatment groups on day 1.  Randomization will be 
stratified by [CONTACT_614759]1c (≥7 to <8.5% or ≥8.5 to 10%). The 
planned doses are 30 mg/day of EGT0001442 or placebo.  Each subject will be provided with 
study drug for [ADDRESS_815332] will be instructed to return to the cl inic on weeks 2, 6, 12, 18, and 24 for safety 
monitoring  and efficacy assessment including review of adverse events, concomitant 
medication, ECG, vital signs, physical examinations, testing of blood chemistry and 
hematology laboratory  parameters, and a uri nalysis.  
Subjects who complete the 24 -week treatment period will continue receiving the study drug 
for an additional 72 weeks.  Subjects who receive rescue medication due to poor glycemic 
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -[ADDRESS_815333] of treatment to control diabetes.  
GLYCEMIC CONTROL  
During the run -in period, subjects will be instructed to determine daily self -monitored blood 
glucose (SMBG) after an overnight fast.  The SMBG record will be reviewed by [CONTACT_614760].  If the fasting blood glucose is > 216 mg/dL (12 mmol/L) in 
two consecutive days, the subject should contact [CONTACT_49885].  In addition, subjects will 
be instructed that they must contact [CONTACT_614761] 24 h if SMBG i s ≥ 270 mg/dL  (15 
mmol/L).  If the fasting SMBG is ≥ 270 mg/dL (15 mmol/L) without explanations for the 
elevation, the investigator will review the SMBG record and determine if the subject should 
attempt to improve diet and exercise to maintain glycemic co ntrol or if the subject must 
discontinue from the study and resume diabetic medications.  Subjects with symptomatic 
hyperglycemia or hypoglycemia should be withdrawn if the symptoms are severe.   
During the [ADDRESS_815334] the clinic if the SMBG is ≥270 mg/dL (15 mmole/L) from 
week 1  (week of randomization) to week 6, ≥240 mg/dL (13.3 mmole/L) from week 6 to 
week 12, or ≥200 mg/dL (11.1 mmole/L) from week 12 to wee k 24.  During the 72 -week 
extension period (weeks 25 to 96), subjects will continue to monitor the SMBG and contact 
[CONTACT_614762] ≥200 mg/dL (11.1 mmole/L).  Values of HbA1c will be evaluated in 
the extension period by [CONTACT_614763]1c is elevated . 
The investigator must review the SMBG record and FPG values in every clinic visit and 
assess whether any subject should receive rescue medications to treat the hyperglycemic 
condition  durin g the [ADDRESS_815335] IVITIES  
The safety monitoring activities will include vital signs, physical examination s, urinalysis, 
adverse events, and concomitant medication use.  The occurrence of blood, liver, or skin 
disorders will be monitored through laboratory testing and adverse event documentation.  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -[ADDRESS_815336] infections (UTIs) and genital infections.  Any adverse 
events that mapped to UTIs or genital infections must be documented.  
DATA AND SAFETY MONIT ORING BOARD (DSMB)  
An independent Data and Safety Monitoring Board (DSMB) will monitor the overall safety 
information during the EGT0001442 development.  The safety review activity and potential 
risk benefit assessment will be defined in the charter.  
MAJOR ADVERSE CARDIOV ASCULAR EVENT ADJUDI CATION  
An independent cardiovascular adjudication committee is established to review the 
cardiovascular events during the study in a blinded fashion.  These events include 
cardiovascular mortality, myocardial infarction, stroke, and hospi[INVESTIGATOR_614742], urgent revascularization procedures, and, other possible serious cardiovascular 
events.  The adjudicated events will be documented and archived to allow a meta -analysis to 
be performed to assess if there is any increase of cardiovascular ri sk to an unacceptable 
extent at the time of completion of all phase [ADDRESS_815337] been treated with other SGLT2 inhibitors, and from previous 
clinical studies in healthy or diabetic subjects treated with EGT0001442 indicate that t he risk 
of induced hypoglycemia as a consequence  of the loss of SGLT2 activity should be minimal.  
Reduction in HbA1c directly reflects improvement in glycemic control and is considered a 
well validated surrogate for the long -term microvascular complications of diabetes mellitus.  
Results from study THR -1442 -C-402 demonstrated that 4 weeks of treatment resulted with a 
dose dependent reduction of 24 – 42 mg/dL FPG in subjects receiving EGT0001442 5 – 50 
mg per day.  Thirty (30) mg/ day of EGT0001442 dosage was chosen in the proposed study 
based on the near saturation of UGE  and FPG decrease in previous cl inical studies in healthy 
or diabetic subjects.  Clinical data in the previous studies indicated that 30 mg/day 
EGT0001442 is well tolerated.  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -[ADDRESS_815338] a maximum of 102 weeks  for the study 
subjects .  The d uration of the overal l study depends  on the rate of patient accrual .  For details 
of the schedule and nature of the investigations, see the Trial Activities Charts in Appendix 1  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -[ADDRESS_815339] the HbA1c between 7% and 10%.  The study will recruit su bjects from 
approximately 50 trial centers in 3 countries.  
4.2 Inclusion Criteria  
1. Male or female subjects ≥18 years old  
2. Diagnosed with type 2 diabetes  
3. Body mass index (BMI) ≤ 37 kg/m2 
4. HbA1c between 7 and 10% (inclusive) at screening  based on an upper limit of  normal 
for the HbA1c assay being 6.5±0.2 %  
5. FPG <250 mg/dL at screening for subjects not treated with oral anti -diabetic therapi[INVESTIGATOR_614743] <240 mg/dL at screening for subjects treated with anti -diabetic therapi[INVESTIGATOR_014]  
6. Diabetes currently treated with diet and exe rcise only or diet and exercise along with 
one approved oral anti -diabetic agent  
7. If taking anti -diabetic medication, dose and regimen must be stable for past [ADDRESS_815340] 3 months  
10. Blood glucose <250 mg/dL based on finger stick blood glucose for all subjects at 
randomization  
11. Subjects willing and able to comply with the investigational nature of the s tudy and 
able to communicate well with investigators.  
12. Able to comprehend and willing to provide written informed consent in accordance 
with institutional and regulatory guidelines.  
 
4.3 Exclusion criteria  
Subjects meet any of the criteria will be excluded:  
1. Hemoglobinopathy that affects HbA1c measurement  
2. Current use of injected therapy for treatment of diabetes (insulin or GLP -1 receptor 
based therapy)  
3. Genitourinary tract infection within [ADDRESS_815341] infections  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -1442 -C-418  02 February 2011   
   
 
Confidential  Page 20 of 61 
 6. eGFR, as calculated by [CONTACT_272256] 
(MDRD), < 50 mL/min/1.73 m2 (Appendix 2 ) 
7. Abnormal tests of liver function ALT, AST or bilirubin ≥ 3x ULRR  
8. Diagnosed with proliferative  retinopathy  
9. Uncontrolled hypertension (blood pressure >150/95)  
10. Not willing to use effective birth control if female with child -bearing potential  
11. Female subjects  who are pregnant or nursing  
12. Life expectancy < 2 years  
13. [LOCATION_001] Heart Association (NYHA)  Class 4 heart failure  
14. Sera positive of HCV , HIV, or positive on drug screen  
15. Currently participating  another interventional trial  
16. Not able to comply the study scheduled visits  
 
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -1442 -C-418  02 February 2011   
   
 
Confidential  Page 21 of 61 
 5 STUDY TREATMENT(S)  
5.1 Description of Treatment(s)  
5.1.1  Study Drug  
Theracos, Inc. will provide EGT00014 42 tablet s in one of the four different strengths as 
follows:  
10 mg SR formulation (E GT0001442 SR Tablet, 10 mg)  
15 mg SR formulation (EGT0001442 SR Tablet, 15 mg)  
20 mg SR formulation (EGT0001442 SR Tablet, 20 mg)  
20 mg IR formulation (EGT0001442 IR Tablet, 20 mg)  
 
The SR tablet formulations consist of EGT0001442 (active pharmaceutical ingredient) and 
excipi[INVESTIGATOR_614744] , lactose monohydrate , sodium bicarbo nate, colloidal silicon 
dioxide and magnesium stearate  in the 10, 15, and 20 mg dosages .  The IR tablet formulation 
consists of 20 mg EGT0001442 (active pharmaceutical ingredient) and excipi[INVESTIGATOR_614745], lactose monohydrate, croscarmellose sodium, colloidal silicon 
dioxide, and magnesium stearate.  
All study drug supplies will be prepared and labeled according  to the requirements of local 
law and legislation and will be kept in a secure storage facility at controlled room  
temperature , 15 – 30°C (59 – 86°F) .  The pharmacist or designated CRO personnel will 
dispense the study drugs  for each subject according  to randomization assignment  made in the 
IVRS . 
5.1.[ADDRESS_815342] of HPMC , 
lactose monohydrate , sodium bicarbo nate, colloidal silicon dioxide and magnesium stearate . 
Placebo will be prepare d in white opaque  tablets  of the same size  and appearance  as the 
active drug  tablets .  All placebo supplies will be prepared and labeled according to the 
requirements of local law and legislation and will be kept in a secure storage facility at  
controlled room  temperature , 15 – 30°C (59 – 86°F) .  The placebo control is packag ed in a 
manner identical to the  active drug product .  The placebo tablets  will be  administered 
identically  to the EGT00014 42 tablets . 
5.1.3  Rescue medications  
Approved anti -diabetic medications will be provided to subjects who met the criteria to 
receive rescue medication due to poor glycemic control.  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -[ADDRESS_815343] kits will be provided and each kit will contain 4 bottles containing 45 
tablets  per bottle.  For study weeks 25 – 96, subject kits will contain [ADDRESS_815344] will dispense the 
medications per investigator’s prescription.   
5.[ADDRESS_815345] ate prior 
to blood draw for FPG and other laboratory testing.  
5.4 Method of Assigning Patients to Treatment Groups  
Eligible subjects who complete the 14 ± 3 day washout period to verify eligibility for the 
study and stability of their diabetes will be randomized to receive EGT0001442 or placebo 
according to a randomization code.  Subjects are assigned to placebo or EGT0001442 at 30 
mg/day in a 1:1 ratio.  The random assig nment of study subjects  to treatment groups will be 
centrally located and managed utilizing an Interactive Voice Response Systems (IVRS).  
Randomization will be stratified by [CONTACT_614759]1c (≥7 to 
<8.5% or ≥8.5 to 10%). This rand omization protocol is designed to balance experimental 
treatments within each center and the baseline HbA1c.  
The study will be conducted at multiple investigative sites and will likely involve variable 
numbers of subjects at each site.  Enrollment will be on a competitive basis but will be 
capped at 30% of the total randomized subjects ( 90 subjects) from one center.  
5.[ADDRESS_815346] randomization number and a drug k it 
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -[ADDRESS_815347]’s condition , the 
investigator will contact [CONTACT_614764].  If unblinding occurs, 
the time and  reason for unblinding  will be recorded  on the CRF and the sponsor must be 
notified within  [ADDRESS_815348] and determine if adjustment of the anti -hypertension drug should be 
adjusted per guideline.  
Subjects may receive any medications for adverse events that are necessary in the 
investigators’ judgment.  Subjects are  permitted to take their prescription medications or 
medicinal supplements.  
Concomitant medications administered at the time of randomization and during the study are 
to be recorded on the CRF.  The medication name, dose, frequency, route of administration , 
date(s) of administration and reason for administration must be recorded.  Glucose for the 
treatment of hypoglycemia will be considered concomitant medication and must be recorded 
on the CRF.  This documentation should continue through the treatment peri od and the 
follow up period.  Medications that a subject receives after enrollment to the study and prior 
to randomization must be recorded in the CRF.  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -[ADDRESS_815349] dose of study medication.  Use of acetaminophen  or multivitamins  in this 
interval is permitted.    
5.7.2  Fluid and Food Intake  
Enrolled diabetic subjects will receive counseling regarding an appropriate diet to achieve 
glycemic control based on standards of medical care in diabetes (ADA, 2008) .  The diet 
should be low in saturated fat, high in fiber, and low in simple carbohydrates and contain 
appropriate caloric intake to maintain weight.  
Subjects will fast for a minimum of [ADDRESS_815350] 150 min/week of 
physical activity  that is appropriate for their physical condition.  
5.[ADDRESS_815351].  
Approximately  0.5 mL plasma sample will be collected and stored at -20oC at each clinic 
visit during the treatment period.  The samples will be shipped to the analytical laboratory in 
batches.  EGT0001442 plasma concentration may be determined from all or a portion of the 
samples to verify the drug exposure.  The results of the analysis will not be disclosed to the 
study team during the 24 week main treatment period until the clinical data for the primary 
analysis are locked.  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -1442 -C-418  02 February 2011   
   
 
Confidential  Page 25 of 61 
 5.9 Packaging and Labeling  
5.9.1  Study drug for main t reatment period  
EGT0001442 tablets  and placebo are packaged in high density polyethylene (HDPE) bottles 
sealed with a child resistant closure.    Each kit will include [ADDRESS_815352] identification, lot 
number, kit number, Sponsor’s name [CONTACT_3816], and the i nvesti gational drug caution 
statement.  
5.9.[ADDRESS_815353] 
identification lot number, the sponsor’s name [CONTACT_3816], and the investi gational drug 
caution statement.  
5.10 Storage and Accountability  
EGT0001442 tablets  and matching placebo will be stored at controlled room temperature , 15 
– 30°C (59 – 86°F) .  The rescue medications will be stored in conditions specified in the 
manufacturers’ labeling information.  
5.[ADDRESS_815354] be destroyed after drug accountability is verified by [CONTACT_614765].  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -[ADDRESS_815355] in his native language . 
6.2 Medical History  
The following information will be collected at the screening period:  
• Demographic information including age, sex, race, and whether a female sub ject is of 
childbearing potential or not  
• Significant medical, surgical history with dates.  
• History of kidney stones, bladder malfunction, or frequent urinary tract infections  
• Incident of genitourinary tract infections in the previous 6 weeks  
• History of smoking, alcoh ol or drug dependence or abuse  
• History of diagnosis with HIV sero-positive acquired immunodeficiency sy ndrome 
(AIDS) or Hepatitis B/C  
• Use of any investigational drug in the previous 30 days  or seven half -lives, whichever is 
longer  
• Prior treatme nt with EGT0001474 or EGT0001442 .  Currently participating another 
interventional trial  or not.  
• Use of aspi[INVESTIGATOR_248], and use of cholesterol -lowering drugs  and any other medications 
including over the counter drugs, vitamins, or dietary supplements within 14 day s 
• Type of diabetes and time of first diagnosis  
• Anti- diabetic or hypertension medication history  
• History of cardiovascular events including angina, hypertension, congestive heart failure, 
atherosclerotic cardiovascular disease, myocardial infarction and diagnosis based on the 
[LOCATION_001] Heart Association class, peripheral edema, and cerebrovascular ischemia (TIA 
or CVA).  
• History of cardiac procedures including any re -vascularization procedures or 
hospi[INVESTIGATOR_363735].  
 
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -1442 -C-418  02 February 2011   
   
 
Confidential  Page 27 of 61 
 6.3 Physical Examination  
A comp lete physical examination will be performed by [CONTACT_614766].  A complete physical examination will include measurement of body 
weight and height (height will be measured only at screening), general  assessment o f all body 
systems  including the skin, head, eyes, ears, nose, throat, neck, thyroid, lungs, heart, 
abdomen, lymph nodes, and extremities.  
An abbreviated physical examination will include body weight and general assessment of the 
skin, heart, lungs and abdomen.  A bbreviated physical examination s will be performed by [CONTACT_614767], unless clinically indicated . 
The body weight must be determined using a scale that is calibrated regularly and no less 
than annually.  
6.[ADDRESS_815356] 3 minutes apart.  
6.5 Electrocardiography  
A 12 -lead electrocardiogram (ECG) will be conducted as listed in study activity chart in 
Appendix 1  and whenever clinically indicated . 
6.6 Diet and exercise counseling  
Enrolled diabetic subjects will receive c ounseling regarding an appropriate diet to aid in  
glycemic control based on standards of medical care in diabetes throughout the study (ADA, 
2008) . 
6.[ADDRESS_815357] is outlined in Appendix 1 .  Clinical laboratory tests  will include the following:  
Table  1. List of Laboratory Tests  
Hematology:  
- Hematocrit (Hct)  
- Hemoglobin (Hgb)  
- Platelet count  Serum Chemistry:  
- Albumin (ALB)  
- Alanine aminotransferase (ALT;  
- Aspartate aminotransferase (AST;  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -1442 -C-418  02 February 2011   
   
 
Confidential  Page 28 of 61 
 - Red blood cell (RBC) count  
- White blood cell (WBC) count with 
differential  
 
Urinalysis:  
- Appearance  
- Bilirubin  
- Color  
- Glucose  
- Ketones  
- Microscopic examination of 
sediment  
- Nitrite  
- Occult blood  
- pH 
- Protein  
- Specific gravity  
- Urobilinogen  
 
Hepatitis screening HBsA g, HBcAg, and 
HCV  
 
Urine d rug screen  
 
Urine h uman chorionic gonadotropin 
(hCG ) (only for females who are not 
diagnosed as postmenopausal)  
 - Blood urea nitrogen (BUN)  
- Calcium (Ca)  
- Carbon dioxide (CO 2) 
- Chloride (Cl)  
- Creatinine  
- Glucose  
- Phosphorus  
- Potassium (K)  
- Sodium (Na)  
- Magnesium  
- Total bilirubin  
- Direct bilirubin  
- Total cholesterol  
- High density lipoprotein 
cholesterol (HDL -C) 
- Low density lipoprotein 
cholesterol (LDL -C, calculated)  
- ApoB  
- Total protein  
- Triglycerides  
- Uric acid  
- Fasting plasma glucose  
- HbA1c  
 
Coagulation:  
- Prothrombin time (PT ) 
 
6.7.2  Sample Collection, Storage, and Shippi[INVESTIGATOR_007]  
[IP_ADDRESS]  Hematology and blood chemistry  
Blood samples for hematology, coagulation, and chemistry will be collected.  Timing of 
collection is described in the Schedule of Events (see Appendix 1 ). 
The study staff will contact [CONTACT_614768] a scheduled clinic visit to confirm the time 
of the visit and to remind the subject of appropriate diet and exercise control, proper fasting, 
and to record the diary card with meals of the day and time that the subject ate prior to the 
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -[ADDRESS_815358] return as soon as can be 
arranged (within 7 days) after proper fasting.   If the [ADDRESS_815359] is not collected within 7 days of 
the visit, the fasting plasma glucose will be considered missing.  
[IP_ADDRESS]  Urinalysis  
Clean -catch, midstream urine samples will be collected per schedule outlined in Section 7.  
Dipstick urinalysis will be conducted.  Microscopy will be conducted if the subject has a 
positive result on any of the dipstick tests that require microscopic follow -up to clarify their 
significance.  
6.[ADDRESS_815360] or designated personnel on day 1 with self 
administered dosing instructions and a dosing  log. 
6.9 Adverse Events Assessments  
6.9.1  Definitions  
An adverse event (AE)  is defined as any new medical problem, or exacerbation of an 
existing pro blem, experienced by a subject while enrolled in the study, whether or not it is 
considered drug -related by [CONTACT_093].  
A serious adverse event (SAE)  includes any event that results in any of the following 
outcomes:  
- death  
- life-threatening, i.e., the subject was, in the opi[INVESTIGATOR_871], at immediate 
risk of death from the event as it occurred.  It does not include an event that, had it 
occurred in a more severe form, might have caused death.  
- persistent or significant disability/incapacity  
- requires in -patient hospi[INVESTIGATOR_34908]  
- congenital anomaly/birth defect  
- other medically significant events that, based upon appropriate medical judgment, 
may jeopardize the subject and may require medical or surgical intervention to 
prevent one of the outcomes listed above, e.g., allergic bronchospasm requiring 
intensive treatment in an emergency room or home, blood dyscrasias or convulsions 
that do not result in hospi[INVESTIGATOR_059], or the development of drug dependency or drug 
abuse.  
 
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -1442 -C-418  02 February 2011   
   
 
Confidential  Page 30 of 61 
 Non-serious adverse events are all events that do not meet the criteria for a "serious" adverse 
event.  
Immediately Reportable Adverse Event (IRAE):   Any serious adverse event or any 
adverse event that necessitates discontinuation of study drug, including pr egnancy.  
Clinical Laboratory Changes:  It is the investigator’s responsibility to review the results of 
all laboratory tests as they become available.  For each abnormal laboratory test result, the 
investigator needs to ascertain if this is an abnormal ( i.e., clinically significant) change from 
baseline for that individual subject. (This determination, however, does not necessarily need 
to be made the first time an abnormal value is observed.  The investigator may repeat the 
laboratory test or request add itional tests to verify the results of the original laboratory tests).  
If this laboratory value is determined to be an abnormal change from baseline for that 
subject, this is considered an AE.  
High serum or plasma glucose (hyperglycemia) and high HbA1c, the disease related 
morbidity, are being followed as the study endpoints and will not be documented as adverse 
events.  If, however, the event fulfills any of the criteria for a “serious” adverse event, it must 
be recorded and reported as such.  
Hypoglycemia will be defined as any FPG or SMBG value < 70 mg/dL.  
Any increase in liver function tests (AST, ALT, or bilirubin ) greater than 3X the ULN for the 
laboratory utilized will be considered a clinical laboratory adverse event.  
Increase in creatini ne from baseline by 0.5 mg/dL or more will be reported as a laboratory 
adverse event.  
Severity:   Adverse events will be graded on a 3 -point scale and reported as indicated on the 
CRF.  The intensity of an adverse experience is defined as follows:  
1 = Mild:  Discomfort noticed, but no disruption to daily activity.  
2 = Moderate:  Discomfort sufficient to reduce or affect normal daily activity.  
3 = Severe:  Inability to work or perform normal daily activity.  
 
Study Drug Causality:  Relationship of an adverse event  to treatment will be assessed as 
follows:  
- Definite: There is a reasonable causal relationship between the study drug and the 
AE, when the event responds to withdrawal of the study drug (dechallenge), and 
recurs with rechallenge by [CONTACT_614769].  
- Probable: There is a reasonable causal relationship between the study drug and the 
AE.  The event responds to dechallenge.  Rechallenge not required.  
- Possible: There is a reasonable causal relationship between the study drug and the 
AE.  Dechalle nge is lacking or unclear.  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -1442 -C-418  02 February 2011   
   
 
Confidential  Page 31 of 61 
 - Not Likely: There is a temporal relationship to study drug administration, but there is 
not a reasonable causal relationship between the study drug and the event.  
- Unrelated: There is not a temporal or causal relationship to the s tudy drug 
administration.  
 
6.9.2  Eliciting and Reporting Adverse Events  
The investigator will periodically assess subjects for the occurrence of adverse events.  In 
order to avoid bias in eliciting adverse events, subjects should be asked the following non -
leadi ng question: "How have you felt since your last visit?"  All adverse events (serious and 
non-serious) reported by [CONTACT_614770].   
In addition, Theracos or its designated personnel must be notified immediately by [CONTACT_614771].  Special attention should be paid to recording hospi[INVESTIGATOR_614746].  
6.9.3  Immediately Reportable Adverse  Events (IRAE)  
The investigator must report any serious adverse ev ent or pregnancy, by [CONTACT_614772].  An Immediately 
Reportable Adverse Event (IRAE) form should be completed a nd sent by [CONTACT_614773] 24 hours of knowledge of the event by [CONTACT_779] . 
Non-serious events that require discontinuation of study drug (including laboratory 
abnormalities) should be reported to Theracos  within [ADDRESS_815361].  
6.9.4  Pregnancy  
Women of childbearing potential (WOCBP) who are sexually active must use an effective 
method  of birth control during the course of the study, in a manner such that risk of failure is 
minimized.  Unless the subject and his/her partner(s) are sterile ( i.e., women who have had a 
hysterectomy or have been postmenopausal for at least 12 consecutive mo nths) or remain 
abstinent, two of the following precautions must be used: vasectomy, tubal ligation, vaginal 
diaphragm, intrauterine device (IUD), birth control pi[INVESTIGATOR_3353], birth control implant, condom or 
sponge with spermicide.  Any single method of birth con trol, including vasectomy and tubal 
ligation, may fail, leading to pregnancy.  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -[ADDRESS_815362] review guidelines about 
study participation for WOCBP.  The topi[INVESTIGATOR_78609]:  
- General information  
- Informed consent form  
- Pregnancy prevention information  
- Drug interactions with hormonal contraceptives.  
- Contraceptives in current use.  
- Guidelines for the fo llow-up of a reported pregnancy.  
 
Prior to study enrollment, WOCBP must be advised of the importance  of avoiding pregnancy 
during trial participation and the potential risk factors for an unintentional pregnancy.  The 
subject must sign an informed consent form stating that the above -mentioned risk factors and 
the consequences were discussed with her.  
During the study, all WOCBP should be instructed to contact [CONTACT_397924] ( e.g., missed or late menstrual cycle).  
If a subject or investigator suspects that the subject may be pregnant prior to study drug 
administration, the study drug administration must be withheld until the results of blood and 
urine pregnancy tests are available.  If the pregnancy is confirmed, the subject must not 
receive the study drug and must not be enrolled in the study.  If pregna ncy is suspected while 
the subject is receiving study treatment, the study drug must be withheld immediately (if 
reasonable, taking into consideration any potential withdrawal risks) until the result of the 
pregnancy is known.  If pregnancy is confirmed, t he study drug will be permanently 
discontinued in an appropriate manner ( e.g., dose tapering if necessary for subject safety) and 
the subject withdrawn from the trial.  [Exceptions to study discontinuation may be considered 
for life -threatening conditions only after c onsultations with a  Theracos  Medical Monitor (see 
Appendix III).]  
The investigator must immediately notify the Medical Monitor of any female subject who 
becomes pregnant within [ADDRESS_815363] unless contraindicated by [CONTACT_8663] ( e.g., x-ray studies).  Ot her appropriate 
pregnancy follow -up procedures should be considered if indicated.  In addition, the 
investigator must report to Theracos , on appropriate Pregnancy Surveillance form(s), follow -
up information regarding the course of the pregnancy, including perinatal and neonatal 
outcome.  Infants will be followed for a minimum of six months.  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -[ADDRESS_815364]’ s treatment is required for the  clinical care and safety.  
Emergency Code Break module in the IVRS is used for such emergency situations.  The 
investigator must confirm the intention to unblind the subject’s treatment to obtain the dose 
information.  Upon completion  of the unblinding , the system will send an alert to designated 
study team members tha t an unblinding event occurred .  Documentation of breaking the blind 
should be recorded in the subject’s medical record with the date and time the blind was 
broken, and the na mes of the personnel involved.  
6.9.6  Follow -up of Adverse Events  
[IP_ADDRESS]  Follow -up of Non -serious Adverse Events  
Non-serious adverse events that are identified on the last scheduled contact [CONTACT_614774].  All non -serious events that are ongoing at this 
time will be recorded as ongoing on the CRF.  
[IP_ADDRESS]  Follow -up of Post Study Serious Adverse Events  
Serious adverse events that are identified on the last scheduled contact [CONTACT_614775] s according to the reporting procedures outlined in 
Section 6.9.[ADDRESS_815365]’s condition.  The investigator should continue to 
report any significant follow -up information to Theracos  up to  the point the event has been 
resolved.   
Any new serious adverse events reported by [CONTACT_614776], and are determined by [CONTACT_614777] d rug, should be reported to Sponsor .  This may include serious 
adverse events that are captured on follow -up telephone contact [CONTACT_397927] ( i.e., up to last scheduled contact). The investigator should 
follow ser ious related adverse events identified after the last scheduled contact [CONTACT_614778], or the subject is lost to follow -up.  The investigator should continue to 
report any significant follow -up information to Sponsor  up to the point the eve nt has been 
resolved.   
Any serious adverse events reported by [CONTACT_614779], and are determined by [CONTACT_614780], should be reported to Sponsor .  This study requires that subjects be 
actively monitored for serious adverse events at least 14 days after discharge from the study.  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -[ADDRESS_815366]  
[IP_ADDRESS]  Genitourinary infections  
Events representing genitourinary infection (e.g. cystitis, urethritis, pyelonephritis, balanitis, 
vulvovaginitis should be carefully evaluated and documentation of signs, symptoms, 
infectious agent (bacterial or fungal), and treatment should be undertaken.  
[IP_ADDRESS]  Renal and urinary disorders  
Events that may be r elated to the diuretic effect of an SGLT2 inhibitor (e.g. nocturia, 
pollakiuria, polyuria, and dysuria) should be carefully evaluated and documented.  
[IP_ADDRESS]  Major Adverse Cardiovascular Event (MACE)  
Evaluation of major adverse cardiovascular events will be undert aken across the 
development program for EGT0001442.  All events that potentially represent myocardial 
infarction, cerebrovascular accident (stroke), acute coronary syndrome, or cardiovascular 
death are to be evaluated by [CONTACT_122371].  
[IP_ADDRESS]  Hypoglyc emia  
Severe hypoglycemia is defined as hypoglycemia with documented  blood glucose 2.8 
mmol/L (50 mg/dL) or symptoms  that promptly resolve with oral carbohydrate, intravenous  
glucose, or glucagon that require the assistance of  medical or paramedical personn el. 
6.[ADDRESS_815367] 
treatment.   
Concomitant medications will be coded u sing the World Health Organization dictionary 
(WHODRUG). A table of concomitant medications based on the anatomic therapeutic 
chemical classification (ATC) and preferred name [CONTACT_272343].  A listing of 
concomitant medications will include all medicati ons taken during the course of the study.  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -1442 -C-418  02 February 2011   
   
 
Confidential  Page 35 of 61 
 Any medications taken prior to the start of the study medication will be listed and 
summarized.  
6.11 Removal of Patients from the Trial or Study Drug  
The investigator may withdraw a patient from any of the following re asons:  
• A protocol violation occurs,  
• A serious or intolerable adverse event occurs,  
• A clinically significant change in a laboratory parameter occurs,  
• The sponsor or investigator terminates the study, or  
• The patient requests to be discontinued from the stud y. 
 
6.12 Other Study Procedures  
Approximately 0.5 mL plasma sample will be collected and stored at -20oC at each clinic 
visit during the treatment period.  The samples will be shipped to the analytical laboratory in 
batches.  EGT0001442 plasma concentration may  be determined from all or a portion of the 
samples to verify the drug exposure.  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -[ADDRESS_815368] up to 21 days (V isit 1 to V isit 2), Run-in period is to be 14±3 days 
(Visit 2 to V isit 3), V isit 3 to V isit 4 window is 14±3 days.  A ll other visit windows are the 
nominal duration from randomization ± 7 days.  
7.1.1  Visit 1 - Screening (weeks –5 to -2) 
The screening can be performed up to 3 weeks from the start of study activities.  During the 
screening period, the following information will be gathered or the indicated procedure will 
be performed:  
• Informed Consent and medical history obtained, and Inclusion/Exclusion criteria 
evaluated  
• Complete ph ysical examination including height and weight  
• Vital Signs: blood pressure, pulse, temperature, respi[INVESTIGATOR_614747] [ADDRESS_815369] 3 min apart  
• [ADDRESS_815370]  
• Blood draw for hematology (CBC with platelets, WBC with differential), serum 
chemistry including FPG, and coagulation as detailed in  section 6. 7.1 
• Urinalysis  
• Urine screen for drugs of abuse.  Drug  screening includes amphetamines, barbiturates, 
cocaine metabolites, opi[INVESTIGATOR_858], benzodiaz epi[INVESTIGATOR_1651], and cannabinoids .  
• Urine pregnancy test (only for females who are not postmenopausal)  
• The subject must be queried to assess compliance with a minimum of a [ADDRESS_815371] should  return within a week after proper fasting.  
 
7.1.2  Visit 2 – run-in period (day -14±3)  
• Confirm eligibility  
• Diet and exercise counseling  
• Glucometer dispensing and training for SMBG determination  
• Discontinue anti -diabetic medication  
• Vital Signs: blood pressure, pulse, temperature, respi[INVESTIGATOR_614747] [ADDRESS_815372] 3 min apart  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -1442 -C-418  02 February 2011   
   
 
Confidential  Page 37 of 61 
 • Dispense study medication for the run -in period  
 
7.2 Primary Efficacy Phase  
7.2.1  Visit 3 – procedures (Day 1 in Week 0)  
 The subject must be queried to assess compliance with a minimum of a [ADDRESS_815373] should  return within a we ek 
after proper fasting.  
• Confirm eligibility  
• Diary and SMBG review  
• Adverse events and pre -treatment medications assessment  
• Randomization  
• Vital Signs: blood pressure, pulse, temperature, respi[INVESTIGATOR_614747] [ADDRESS_815374] 3 min apart  
• [ADDRESS_815375]  
• Dispense study medication based on randomization assignment  
• Blood draw for hematology (CBC with platelets , WBC with differential), serum 
chemistry including FPG, and coagulation as detailed in  section 6. 7.1 
• Urinalysis  
 
7.2.2  Visit 4 – Procedures (week 2)  
 The subject must be queried to assess compliance with a minimum of a [ADDRESS_815376] should  return within a week 
after proper fasting.  
• Diary and SMBG review  
• Vital Signs: blood pressure, pulse, temperature, respi[INVESTIGATOR_614748] [ADDRESS_815377] 3 min apart  
• Blood draw for hematology (CBC with platelets, WBC with differential), serum 
chemistry including FPG, and coagulation as detai led in  section 6. 7.1 
• Urinalysis  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -1442 -C-418  02 February 2011   
   
 
Confidential  Page 38 of 61 
 • Collect plasma sample for drug exposure verification  
• Assess adverse events and record concomitant medications  
 
7.2.3  Visit 5 – Procedures (week 6)  
 The subject must be queried to assess compliance with a minimum of a [ADDRESS_815378] should  return within a week 
after proper fasting.  
• Diary and SMBG review  
• Vital Signs: blood pressure, pulse, temperature, respi[INVESTIGATOR_614747] [ADDRESS_815379] 3 min apart  
• Dispense study medication  
• Blood draw for hematology (CBC with platelets, WBC with differential), serum 
chemistry including FPG, and coagulation as detailed in  section 6. 7.1 
• Urinalysis  
• Collect plasma sample for drug exposure verification  
• Assess adverse events and record concomitant medications  
 
7.2.4  Visit 6 – Procedures (week 12)  
 The subject must be queried to assess compliance with a minimum of a [ADDRESS_815380] should  return within a we ek 
after proper fasting.  
• Diary and SMBG review  
• Diet and exercise counseling  
• Physical examination  
• Vital Signs: blood pressure, pulse, temperature, respi[INVESTIGATOR_614747] [ADDRESS_815381] 3 min apart  
• Dispense study medication  
• Blood draw for hematology (CBC with platelets, WBC with differential), serum 
chemistry including FPG, and coagulation as detailed in  section 6.7.1  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -1442 -C-418  02 February 2011   
   
 
Confidential  Page 39 of 61 
 • Urinalysis  
• Collect plasma sample for drug expos ure verification  
• Assess adverse events and record concomitant medications  
 
7.2.5  Visit 7 – Procedures (week 18)  
 The subject must be queried to assess compliance with a minimum of a [ADDRESS_815382] should  return within a week 
after proper fasting.  
• Diary and SMBG review  
• Vital Signs: blood pressure, pulse, temperature, respi[INVESTIGATOR_614749] a t least [ADDRESS_815383] 3 min apart  
• Dispense study medication  
• Blood draw for hematology (CBC with platelets, WBC with differential), serum 
chemistry including FPG, and coagulation as detailed in  section 6. 7.1 
• Urinalysis  
• Collect plasma sample for drug exposure verification  
• Assess adverse events and record concomitant medications  
 
7.2.6  Visit 8 – Procedures (week 24)  
 The subject must be queried to assess compliance with a minimum of a [ADDRESS_815384] should  return within a week 
after proper fasting.  
• Diary and SMBG review  
• Diet and exercise counseling  
• Physical exa mination  
• Vital Signs: blood pressure, pulse, temperature, respi[INVESTIGATOR_614747] [ADDRESS_815385] 3 min apart  
• [ADDRESS_815386]  
• Dispense study medication  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -1442 -C-418  02 February 2011   
   
 
Confidential  Page 40 of 61 
 • Blood draw for hematology (CBC with platelets, WBC with differential), serum 
chemistry including FPG, and coagulation as detailed in  section 6. 7.1 
• Urinalysis  
• Collect plasma sample for drug exposure verificati on 
• Assess adverse events and record concomitant medications  
 
7.3 Extension Phase  
7.3.1  Visit 9 – Procedures (week 36)  
 The subject must be queried to assess compliance with a minimum of a [ADDRESS_815387] should  return within a week 
after proper fasting.  
• Diary and SMBG review  
• Vital Signs: blood pressure, pulse, temperature, respi[INVESTIGATOR_614750] [ADDRESS_815388] 3 min apart  
• Dispense study medication  
• Blood draw for hematology (CBC with platelets, WBC with differential), serum 
chemistry including FPG, and coagulation as detailed in  section 6. 7.1 
• Urinalysis  
• Collect plasma sample for drug exposure verification  
• Assess adverse events and record concomitant medications  
 
7.3.2  Visit 10 – Procedures (week 48)  
 The subject must be queried to assess compliance with a minimum of a [ADDRESS_815389] should  return within a we ek 
after proper fasting.  
• Diary and SMBG review  
• Diet and exercise counseling  
• Physical examination  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -1442 -C-418  02 February 2011   
   
 
Confidential  Page 41 of 61 
 • Vital Signs: blood pressure, pulse, temperature, respi[INVESTIGATOR_614747] [ADDRESS_815390] 3 min apart  
• Dispense study medication  
• Blood draw for hematology (CBC with platelets, WBC with differential), serum 
chemistry including FPG, and coagulation as detailed in  section 6. 7.1 
• Urinalysis  
• Collect plasma sample for drug expos ure verification  
• Assess adverse events and record concomitant medications  
 
7.3.3  Visit 11 – Procedures (week 60)  
 The subject must be queried to assess compliance with a minimum of a [ADDRESS_815391] should  return within a week 
after proper fasting.  
• Diary and SMBG review  
• Vital Signs: blood pressure, pulse, temperature, respi[INVESTIGATOR_614747] [ADDRESS_815392] 3 min apart  
• [ADDRESS_815393]  
• Dispense study medication  
• Blood draw for hematology (CBC with platelets, WBC with differe ntial), serum 
chemistry including FPG, and coagulation as detailed in  section 6. 7.1 
• Urinalysis  
• Collect plasma sample for drug exposure verification  
• Assess adverse events and record concomitant medications  
 
7.3.4  Visit 12 – Procedures (week 72)  
 The subject must be queried to assess compliance with a minimum of a [ADDRESS_815394] should  return within a we ek 
after proper fasting.  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -1442 -C-418  02 February 2011   
   
 
Confidential  Page 42 of 61 
 • Diary and SMBG review  
• Diet and exercise counseling  
• Physical examination  
• Vital Signs: blood pressure, pulse, temperature, respi[INVESTIGATOR_614747] [ADDRESS_815395] 3 min apart  
• Dispense study medication  
• Blood draw for hematology (CBC with platelets, WBC with differential), serum 
chemistry including FPG, and coagulation as detailed in  section 6. 7.1 
• Urinalysis  
• Collect plasma sample for drug expos ure verification  
• Assess adverse events and record concomitant medications  
 
7.3.5  Visit 13 – Procedures (week 84)  
 The subject must be queried to assess compliance with a minimum of a [ADDRESS_815396] should  return within a week 
after proper fasting.  
• Diary and SMBG review  
• Vital Signs: blood pressure, pulse, temperature, respi[INVESTIGATOR_614747] [ADDRESS_815397] 3 min apart  
• Dispense study medication  
• Blood draw for hematology (CBC with platelets, WBC with differential), serum 
chemistry including FPG, and coagulation as detailed in  section 6. 7.1 
• Urinalysis  
• Collect plasma sample for drug exposure verification  
• Assess adverse events and record concomitant medications  
 
7.3.6  Visit 14 – Procedures (week 96)  
 The subject must be queried to assess compliance with a minimum of a [ADDRESS_815398] prior to 
blood draw to ensure the FPG values can be accurately determined.  Only water is 
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -[ADDRESS_815399] should  return within a week 
after proper fasting.  
• Diary and SMBG review  
• Physical examination  
• Vital Signs: blood press ure, pulse, temperature, respi[INVESTIGATOR_614747] [ADDRESS_815400] 3 min apart  
• [ADDRESS_815401]  
• Blood draw for hematology (CBC with platelets, WBC with differential), serum 
chemistry including FPG, and coagulation as detailed in  section 6. 7.1 
• Urinalysis  
• Collect plasma sample for drug exposure verification  
• Assess adverse events and record concomitant medications  
 
7.3.7  Visit 15 – Exit Visit (week 97)  
Follow -up is planned at approximately one week after the last dose is administered.  If 
subjects have an ongoing adverse event, the subject will be followed until the adverse event 
is resolved or returns to base line. All possible attempts will be made to document resolution 
of acute and chronic toxicities. Diary and SMBG review  
• Physical examination  
• Vital Signs: blood pressure, pulse, temperature, respi[INVESTIGATOR_614747] [ADDRESS_815402] 3 min apart  
• [ADDRESS_815403]  
• Blood draw for hematology (CBC with platelets, WBC with differential), serum 
chemistry including FPG, a nd coagulation as detailed in  section 6. 7.1 
• Urinalysis  
• Assess adverse events and record concomitant medications  
 
7.[ADDRESS_815404] 
withdraws or is withdrawn from the study.  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -[ADDRESS_815405] a follow -up 
examination, including a complete physical examination, vital s igns, ECG, CBC, urinalysis, 
and serum chemistry tests.  
 
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -[ADDRESS_815406] 
performance of the study procedures and assure that the study will be conducted ac cording to 
the protocol and relevant regulatory requirements.  CRF entries will be verified with the 
source documentation.  
Quality control principles will be applied throughout the performance of this study by 
[CONTACT_614781].  Review procedures will be implemented at 
the CRO for all documents that are generated in relation to the study.  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -1442 -C-418  02 February 2011   
   
 
Confidential  Page 46 of 61 
 9 PLANNED STATISTICAL  METHODS  
9.1 General Considerations  
The primary objective of this trial is to assess the efficacy of EGT0001442 in treatment -naïve 
type-2 diabetic patients or patients on a single oral anti -diabetic drug in combination with 
diet and exercise with an HbA1c between 7 and 10%.  Efficacy, in this case, is defined as a 
significant reduction in HbA1c at week [ADDRESS_815407] of 
EGT0001442 on fasting glucose, blood pressure, body weight and the general safety of 
EGT0001442 in patients with T2DM will also be explored.  
Statistical analyses and summaries of safety and tolerability will be performed using S AS® 
software (SAS Institute, Cary, NC).  In all cases, significance will be judged at the =0.[ADDRESS_815408].   
9.1.2  Multiple Comparisons / Multiplicity  
There is a single primary endpoint  in this study and no correction for multiple comparisons is 
needed.  Important secondary endpoints are considered exploratory and will not be corrected.  
9.2 Determination of Sample Size  
Approximately 300 patients will be enrolled and equitably allocated to re ceive either 20 
mg/day EGT0001442 or placebo.   
The sample size of 150 subjects per group was calculated based on the following 
assumptions:  
1.  This effect size is the mean difference between baseline and week 24.  The active 
doses will decrease  the HbA1c b y 0.4%.  
2. The placebo will not experience a substantive average decrease in mean HbA1c from 
baseline to week 24  
3. The standar d deviation  of this difference is the same for both groups and is  1.0%.   
4. The study design is balanced and the two -sided significance l evel for the hypothesis 
is 0.05.   
 
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -1442 -C-418  02 February 2011   
   
 
Confidential  Page 47 of 61 
 Under the above assumptions, an evaluable sample size of 131 evaluable patients per 
treatment arm yields approximately 90% power that EGT0001442 treatment will be found to 
be significantly different from placebo.  A sampl e size of [ADDRESS_815409] -to-follow -up. 
9.3 Analysis Populations  
This study will be conducted at multiple investigative sites and will likely involve variable 
numbers of subjects at each site.  E nrollment will be on a competitive basis but will be 
capped at 90 subjects in one center.  
All patients in the Intent -to-Treatment (ITT) sample will be analyzed according to the 
treatment they were randomized to receive, and not according to what they actua lly received, 
if different.  All efficacy analyses will be performed on the ITT sample . All patients in the 
Per Protocol (PP) sample will be analyzed according to the treatment actually received, and 
not according to the treatment they were randomized to r eceive, in the event there is a 
discrepancy .  The analyses of primary efficacy endpoint and selected secondary efficacy 
endpoints will be performed on the PP sample .  The Safety sample will include all 
randomized patients who have received study drug.  The  safety sample will be used for safety 
analysis.  
9.[ADDRESS_815410] meet all inclusion criteria and none of the exclusion criteria in order to 
participate in the study.  Demographic characteristics include age, gender, race, ethnicity, and 
study center.  Baseline characteristics include baseline HbA1c values, blood pressure, Body 
Mass Index (BMI in kg/m2), whether treatment naïve or not .  Summary descriptive statistics 
will include counts and percentages for discrete var iables and estimation of means, standard 
deviations, medians, inter -quartile range, minimum and maximum for continuous metrics.  
9.5 Analysis of Efficacy  
Efficacy data includes HbA1c, FPG, body weight, systolic and diastolic blood pressure, and 
% of subject who achieve HbA1c <7%  at week [ADDRESS_815411] to week 24.    
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -[ADDRESS_815412] secondary hypothesis is that EGT0001442 reduces FPG at weeks 2 
and 24 when compar ed to controls.  Change in FPG for each follow up visit will be estimated 
as follow -up minus baseline and the two treatment groups will be compared with two paired 
t-tests.  
The second hypothesis is that EGT0001442 reduces the HbA1c to less that 7% of more 
patients when compared to placebo.  HbA1c categories will be assessed for each patient as 
<7% or ≥7% of each subject.  The 2x2 contingency table of treatment by [CONTACT_13505]1c category 
will be analyzed with a test.  
The third hypothesis is that EGT0001442 reduce s blood pressure compared to placebo.  
Systolic and Diastolic blood pressure will be measured at baseline and at weeks [ADDRESS_815413] of demographic covariates such as gender, race, age, treatment center, will be 
evaluated on the primary endpoint and selected secondary endpoints (FPG, blood pressure, 
and body weight) using Analysis of Covariance.  Demo graphic variables will be included in 
the model of change in the dependent variable with treatment.  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -1442 -C-418  02 February 2011   
   
 
Confidential  Page 49 of 61 
 9.6 Analysis of Safety  
Safety data includes adverse events (AEs), physical exam results, vital signs, ECG results, 
and clinical lab results including serum che mistry, hematology, and urinalysis. Observed data 
will be described as  counts and percentages for discrete variables and estimation of means, 
standard deviations, medians, inter -quartile range, minimum and maximum for continuous 
metrics.  All patients will  be included in the safety analysis.   All safety data will be presented 
in by -subject listings and included in the clinical trial report.  
9.6.1  Adverse Events  
Adverse events will be mapped to preferred term and body system using the Medical 
Dictionary for Regula tory Activities (MedDRA) dictionary. The number and percentage of 
patients reporting adverse events will be determined by [CONTACT_614782]. Drug -related adverse events will be considered those to be at least 
possibly r elated to EGT0001442 administration.  
Adverse event listings will be provided for the following subsets:  
• All treatment emergent AEs (TEAEs)  
• All TEAEs at least possibly related to EGT0001442  
• Serious TEAEs (if any)  
• TEAEs leading to study discontinuati on (if any)  
 
AEs are treatment emergent if occurring on or after EGT0001442 administration. TEAEs 
will be considered at least possibly related to EGT0001442 based on the investigators 
assessment. Only TEAEs will be tabulated in summary tables.  
Tabulations will display TEAEs by [CONTACT_926], and relationship to EGT0001442.  
9.6.[ADDRESS_815414]  
[IP_ADDRESS]  Genitourinary infections  
Genitourinary infections as defined in Section [IP_ADDRESS] will be summarized.  Event terms, 
signs, symptoms, infectious agent (bacterial or fungal), and treatment undertaken will be 
documented in the listing.  
[IP_ADDRESS]  Major Adverse Cardiovascular Event (MACE)  
All events that potentially represent myocardial infarction, cerebrovascular accident (stroke), 
acute coronary syndrome, or cardiov ascular death are to be evaluated by [CONTACT_530770].  There will not be any analysis performed.  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -1442 -C-418  02 February 2011   
   
 
Confidential  Page 50 of 61 
 [IP_ADDRESS]  Hypoglycemia  
Severe hypoglycemia as defined in Section [IP_ADDRESS] will be presented in a listing and 
summarized.  
[IP_ADDRESS]  Renal and Urinary disorders  
Events as defined in Section [IP_ADDRESS] will be summarized.  Event terms, signs, and symptoms 
will be documented in the listing.  
9.6.3  Clinical and Laboratory Events and Analyses  
Clinical and laboratory metrics are measured at baseline and weeks 2, 6, 12 and 24 du ring the 
study.  During the treatment extension they are measured every 12 weeks up to a total of 96 
weeks.  These variables include vital signs (blood pressure, respi[INVESTIGATOR_1516], and temperature), 
Clinical laboratory (see section 6.[ADDRESS_815415]) and E CGs.  
Laboratory data will be summarized using Low -Normal -High shift tables.  ECG results will 
be summarized as changes from baseline in intervals.  Abnormalities as well as changes from 
previous assessment will be listed.  
9.6.4  Concomitant Medications  
Concomitan t medications will be coded using the World Health Organization Drug 
Dictionary (WHODRUG).  A by -subject listing of concomitant medications will include all 
medications taken during the study.  All medications started prior to the administration of the 
study drug will be included in the data but will be flagged as prior.  Only the concomitant 
medication use will be summarized.  
9.[ADDRESS_815416] (DSMB) will monitor the safety of this 
study.  The objectives of th e DSMB are to assess drug safety and allow for protocol 
modification or early stoppi[INVESTIGATOR_397899].  The DSMB members will include at 
least one statistician, one clinician of relevant specialty , and one endocrinologist that is 
familiar with the care of patients with type 2 diabetes.  No interim efficacy assessment will 
be performed.  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -[ADDRESS_815417] details of participating investigators, monitors, clinical laboratories, technical 
departments and/or institutions, as well as information on members of additional study 
committees, will be found in the study files of the study sites . 
10.[ADDRESS_815418]  (IRB) or Independent Ethics Committee 
(IEC) Approval  
This protocol, informed consent document, relevant supporting information, and all types of 
subject recruitment or advertisement information must be submitted to the IEC or IRB for 
review and must be approved by [CONTACT_614783]/ IRB before the study is initiated.  
Any amendments or addenda to the protocol must also be approved by [CONTACT_6179]/ IRB prior to 
implementing changes in the study.  The Investigator is responsible for keepi[INVESTIGATOR_436419]/ IRB 
apprised of the progress of the study and of any changes made to the protocol as deemed 
appropriate, but in any case at least once a year.  The Investigator must also keep the 
IEC/ IRB informed of any SAEs occurring to subjects under the ir supervision.  
10.[ADDRESS_815419], evaluation, and 
documentation of this study, are designed to ensure that the sponsor and investigator abide by 
[CONTACT_614784] s and under the guiding principles detailed in the 
Declaration of Helsinki. The study will also be carried out in keepi[INVESTIGATOR_23577](s) and regulation(s). This may include an inspection by [CONTACT_614785]/or their designee an d/or FDA representatives at any time. The investigator must agree to 
the inspection of study -related records by [CONTACT_1622]/sponsor representatives, and must allow 
direct access to source documents to the FDA/sponsor representatives.  
The investigator is respon sible for complying with the protocol and all appropriate 
regulations and guidelines governing global clinical research. Additionally, he/she is 
responsible for ensuring that all participating staff members are adequately trained and 
competent to perform h is/her assigned tasks.  
Modifications to the study protocol will not be implemented by [CONTACT_23664]. However, the investigator may implement a 
deviation form, or a change of, the protocol to elimin ate an immediate hazard(s) to the trial 
subjects without prior IRB/sponsor approval/favorable opi[INVESTIGATOR_1649]. As soon as possible, the 
implemented deviation or change, the reasons for it and if appropriate the proposed protocol 
amendment should be submitted to th e IRB/sponsor.  
Any deviations from the protocol must be fully explained and documented by [CONTACT_1275]. The circumstances, action taken and impact of the deviation on the trial must be 
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -[ADDRESS_815420] the EC/IRB written approval/ 
favorable opi[INVESTIGATOR_614751]. The written approval of the EC/IRB together with the approved 
subject information/Informed Consent Forms must be filed in the study files. The Informed 
Consent Form must  contain all elements required by [CONTACT_93364] 21 CFR Part 50 and the 
International Conference on Harmonisation (ICH) Good Clinical Practices (GCP) Guidelines 
(E6) in addition to any other elements required by [CONTACT_54443], local or institutional policy.   
Writte n informed consent must be obtained before any study specific procedure takes place. 
Participation in the study and date of informed consent given by [CONTACT_272286]’s files. A copy of the signed informed conse nt form 
must be provided to the subject.  If applicable, it will be provided in a certified translation in 
the language understood by [CONTACT_614786].  Signed consent forms must remain in 
each subject’s study file and must be available for verif ication by [CONTACT_9534].  
10.[ADDRESS_815421]’s permission.  To 
ensure compliance with current ICH guidelines, data generated by [CONTACT_614787], the Sponsor and the IRB for each study site.  
Subject names and other identifiers, such as photographs, audio or videotapes, may not be 
disclosed in any publication without prior written authorization from the subject.  
10.[ADDRESS_815422] study data, subjects’ 
medical records and CRFs in accordance with ICH guidelines, GCPs and the respective local 
and national government regulations and guidelines.  
The Investigator will permit authorized representatives of the Sponsor and the respective 
national or local health authorities to inspect facilities and records relevant to this study.  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -[ADDRESS_815423] consented, a case report form (CRF)  will be supplied and maintained by [CONTACT_614788]/she has 
reviewed and agrees with the entered data. This also applies to those subjects who fail to 
complete the trial. The reason a subject is withdrawn must be recorded in the case report 
form.  
Entries made in the CRF must be verifiable against source documents. Source documents are 
defined as all medical records, medical notes, laboratory results, ECG traces and any 
additional docume nt other than the CRF that has original subject information contained 
within it.  The diary card that subjects will complete with meal information will be archived 
but meal information will not be entered in the database.  Whether the subject was fasting f or 
10 hr or not prior to sample collection will be captured in the CRF.  
All CRFs and source documents should be completed following GCPs and the CRO’s 
standard operating procedures.  
10.8 Protocol Violations/ Deviations  
Protocol “violations” include deviations fr om the inclusion and exclusion criteria, 
concomitant medication restrictions, and any other protocol requirement that results in a 
significant added risk to the patient  or has an impact on the quality of the data collected or 
the outcome of the study.  Protocol violations must be reported to the Ethics Committee or 
Institutional Review Board in a timely manner.  Protocol violations must be reported in the 
final study report.  
A protocol deviation  occurs when there is non -adherence to study procedures or sc hedules, as 
specified by [CONTACT_760], which do es not involve inclusion/exclusion criteria or the primary 
endpoint and which do es not place the patient  at any added risk or affect  the data quality or 
study outcome .  If deviations occur, such as a missed vi sit or missed sampling window, the 
investigator must decide whether to proceed, for example, whether or not to complete the 
visit or sample collection outside of the protocol -defined window.  The sponsor’s medical 
monitor must be notified immediately when protocol deviations are discovered so that a 
decision can be made about the continued participation of the subject in the study.  
A departure from the protocol for an individual subject can only be made without the 
Sponsor approval in the event of an emerge ncy.  The nature and reasons for the protocol 
deviation will be recorded in the CRF and the Principal Investigator [INVESTIGATOR_272216].  
10.[ADDRESS_815424] 
medical records and CRFs in accordance with ICH guidelines, GCP and the respective local 
and national government regulations and guidelines.  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -[ADDRESS_815425] facilities and records relevant to this study.  
Each center will be visited at regular intervals by a monitor to ensure compliance with the 
study protocol, GCP and legal aspects. This will include on -site checking of the case report 
forms (CRF) for completeness and clarity, cross -checking with source documents, and 
clarification of administrative matters.  
All CRF data will be entered into a clinical database.  Following the correction of any errors, 
the clinical database will b e locked.  
10.[ADDRESS_815426] who is randomized to receive study drug, a case report form (CRF) must be  
maintained by a trial coordinator and signed by [CONTACT_614789]/she has reviewed a nd agrees with the entered data.  This also applies to those 
subjects who fail to complete the trial.  The reason a subject is withdrawn must be recorded 
in the CRF.  Subjects whose eligibility is not confirmed on day [ADDRESS_815427] be 
made, initialed and dated by [CONTACT_36324].  
The Sponsor or designated CRO is responsible for data processing and data query.  The 
investigator or designated staff is responsible for query resolution and data clarif ication.  
10.11  Retention of Data  
The study file and all source data should be retained until notification given by [CONTACT_267436].  If the investigator withdraws from the trial and relinquishes his/her 
responsibility for the maintenance and retentio n of records, he/she must notify the Sponsor in 
writing so arrangements can be made to properly store the trial materials.  
10.12  Publication and Disclosure Policy  
All data and results and all intellectual property rights in the data and results derived from the 
study will be the property of the Sponsor, who may utilize the data in various ways, such as 
for submission to government regulatory authorities or disclosure to other investigators.  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -1442 -C-418  02 February 2011   
   
 
Confidential  Page 55 of 61 
 No publication or disclosure of study results will be permitted except as  specified in a 
separate, written agreement between Theracos, Inc. and the investigator.  If results of this 
study are reported in medical journals or at meetings, all subjects’ identities will remain 
confidential.  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -[ADDRESS_815428]  
ADA (200 8). Standards of medical care in diabetes --2008. Diabetes Care  [ADDRESS_815429] 1 , S12 -54. 
Ehrenkranz, J.R., Lewis, N.G., Kahn, C.R., and Roth, J. (2005). Phlorizin: a review. Diabetes 
Metab Res Rev  21, 31-38. 
Ferrannini, E., Ramos, S.J., Salsali, A., Tang, W., an d List, J.F. (2010). Dapagliflozin 
monotherapy in type 2 diabetic patients with inadequate glycemic control by [CONTACT_543065]: a randomized, double -blind, placebo -controlled, phase 3 trial. Diabetes Care  33, 
2217 -2224.  
Han, S., Hagan, D.L., Taylor, J.R. , Xin, L., Meng, W., Biller, S.A., Wetterau, J.R., 
Washburn, W.N., and Whaley, J.M. (2008). Dapagliflozin, a selective SGLT2 inhibitor, 
improves glucose homeostasis in normal and diabetic rats. Diabetes  57, 1723 -1729.  
Komoroski, B., Vachharajani, N., Boult on, D., Kornhauser, D., Geraldes, M., Li, L., and 
Pfister, M. (2009a). Dapagliflozin, a novel SGLT2 inhibitor, induces dose -dependent 
glucosuria in healthy subjects. Clin Pharmacol Ther  85, 520 -526. 
Komoroski, B., Vachharajani, N., Feng, Y., Li, L., Kornha user, D., and Pfister, M. (2009b). 
Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks 
in patients with type 2 diabetes mellitus. Clin Pharmacol Ther  85, 513 -519. 
Neumiller, J.J., White, J.R., Jr., and Campbell, R.K. ( 2010). Sodium -glucose co -transport 
inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs  70, 377 -385. 
Santer, R., Kinner, M., Lassen, C.L., Schneppenheim, R., Eggert, P., Bald, M., Brodehl, J., 
Daschner, M., Ehrich, J.H., Kemper , M., et al.  (2003). Molecular analysis of the SGLT2 gene 
in patients with renal glucosuria. J Am Soc Nephrol  14, 2873 -2882.  
Sicree, R., Shaw, J., and Zimmet, P. (2010). The Global Burden - Diabetes and Impaired 
Glucose Tolerance (Baker IDI Heart and Diabe tes Institute).  
van den Heuvel, L.P., Assink, K., Willemsen, M., and Monnens, L. (2002). Autosomal 
recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter 
(SGLT2). Hum Genet  111, 544 -547. 
 
 
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -1442 -C-418  02 February 2011   
   
 
Confidential  Page 57 of 61 
 Appendix 1  Schedule of Events  
 Screening 
& Run-in Primary Efficacy Phase  Extension Phase  
Visit Number  1 2 3 4 5 6 7 8 9 10 11 12 13 14 ET 
Time Relative to Randomization Visit 
(weeks)1 -5 -2 0 2 6 12 18 24 36 48 60 72 84 96  
Informed Consent  X               
Screening for I/E criteria  X X X             
Medical History  X               
Diet & exercise counseling   X    X  X  X  X    
Diary Review    X X X X X X X X X X X X X 
Discontinue anti -diabetic medication   X              
Randomization    X             
Physical exam  X     X  X  X  X  X X 
Vital signs  X X X X X X X X X X X X X X X 
ECG  X  X     X   X   X X 
Dispense study medication   X X  X X X X X X X X X   
Blood draw for clinical lab test2 X  X X X X X X X X X X X X X 
PK sample     X X X X X X X X X X X  
Urinalysis3 X  X X X X X X X X X X X X X 
AE4   X X X X X X X X X X X X X 
Con Med    X X X X X X X X X X X X X 
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -[ADDRESS_815430] up to 21 days (V1 to V2), Run -in period is to be 14±3 days (V2 to V3), V3 to V4 window is 14±3 days, all other visit windows 
are the nominal duration from randomization ± 7 days.  
2 Blood sample for these lab tests at the designated visit:  
V1: CBC, electrolytes, BUN, creatinine, Lipi[INVESTIGATOR_805] (TG, TC, HDL -C), ALT, AST, bilirubin (total and direct), PT, HbA1c,  FPG,  TSH, aPTT, Hepatitis Screen 
(HBsAg, HBcAg, HCV)  
V3: CBC, electrolytes, BUN, creatinine, Lipi[INVESTIGATOR_805] (TG, TC, HDL -c), ALT, AST, bilirubin (total and direct), HbA1c, FPG  
V4: CBC, electrolytes, BUN, creatinine, HbA1c, FPG  
V5: CBC, electrolytes, BUN, creatinine, HbA1c, FPG  
V6: CBC, electrolytes, BUN, creatinine, Lipi[INVESTIGATOR_805] (TG, TC, HDL -c), ALT, AST, bilirubin (total and direct), HbA1c, FPG  
V7: CBC, electrolytes, BUN, creatinine, HbA1c, FPG  
V8-V14 and ET: CBC, electrolytes, BUN, creatinine, Lipi[INVESTIGATOR_805] (TG, TC, HDL -c), ALT, AST, bilirubin (total and direct), HbA1c, FPG  
[ADDRESS_815431] and drug screen on screening (visit 1)  
[ADDRESS_815432] are specified to be:  
 Cardio - and cerebro - vascular events,  
 Genitourinary infections  
 Increase in creatinine from baseline by 0.5 mg/dL or more  
 Increase in ALT, AST or bilirubin to >3x ULRR  
 
 
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -1442 -C-418  02 February 2011   
   
 
Confidential  Page 59 of 61 
 Appendix 2  Estimating glomerular filtration rate  
Estimating the glomerular filtrati on rate (eGFR), as calculated by [CONTACT_614790] (MDRD), should be calculated based on following equation:  
GFR (mL/min/1.73 m2) = 175 x (S cr)-1.154 x (Age)-0.203 x (0.742 if female) x (1.212 if African 
American) (conventional units)  
 
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -1442 -C-418  02 February 2011   
   
 
Confidential  Page 60 of 61 
 Appendix 3  Sponsor Signatures  
Study Title:  Efficacy and safety of EGT0001442 compared with placebo in 
patients with type 2 diabetes mellitus inadequately controlled by [CONTACT_614791] -diabetes agent.  
Study Number:  THR -1442 -C-418 
Final Date:  [ADDRESS_815433] to critical review and has been approved by [CONTACT_103]. The follow ing personnel contributed to writing and/or approving this protocol:  
 
 
Signed:    Date:    
Yuan -Di Halvorsen, Ph.D .  
Protocol Originator  
Consultant for Theracos, Inc.  
 
 
Signed:    Date:    
R. Paul Aftring, M.D., Ph.D .  
Medical Director  
Consultant for Theracos,  Inc. 
 
 
Signed:    Date:    
Ulrich Granzer, Ph.D .  
Regulatory Affairs  
Consultant for Theracos Inc.  
EGT0001442 tablet   Theracos, Inc.  
Clinical Trial Protocol : THR -1442 -C-418  02 February 2011   
   
 
Confidential  Page 61 of 61 
 Appendix 4  Investigator’s Signature  
[CONTACT_2759]:  Efficacy and safety of EGT0001442 compared with placebo in 
patients with type 2 diabetes mellitus inadequately controlled by [CONTACT_614791] -diabetes agent.  
Study Number:  THR -1442 -C-418 
Final Date:  [ADDRESS_815434] the study as described in the protocol.  
 
 
 
Signed:    Date:    
Principal Investigator  
 
 
 